Improving opioid treatment and HIV prevention in prisons
Official title: PRIDE III Prison Interventions and HIV Prevention Collaboration
Run by Yale University · NCT06962033 · Data updated 2026-11-12
This study is trying to find out what makes it hard to provide opioid treatment in prisons in Tajikistan, Kyrgyzstan, Moldova, and Georgia, so that they can improve care for people with addiction and help prevent HIV.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Yale University Academic / other |
| Locations | 5 sites (New Haven, Connecticut and 4 other locations) |
| Status | Recruiting |
| Started | November 5, 2024 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT06962033 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include probation officers and individuals currently on probation who have a history of opioid injection.
✕Probably not a fit
Patients not currently involved in the justice system or those without a history of opioid use may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to identify barriers to the implementation of Opioid Agonist Therapy (OAT) within the justice systems of Tajikistan, Kyrgyzstan, Moldova, and Georgia. It involves creating NIATx learning collaboratives with prison OAT providers and probation officers to enhance the scale-up of OAT. Data will be collected from national OAT databases and through surveys administered to prison narcologists and probation officers every six months. Additionally, ethnographic methods will be employed to observe and interview probation clients and staff.
Why it matters
Potential benefit: If successful, this initiative could significantly improve access to opioid treatment and reduce HIV transmission among incarcerated populations.
How similar studies have gone: Previous studies have shown promise in implementing OAT in similar settings, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Aim 1: 1. Quantitative surveys for prison OAT providers * Being 18 years or older * Being currently assigned and working as a probation OAT provider for a probation site 2. ECHO procedures Aim 2: 1. Quantitative surveys for people in probation * Being 18 years or older * Screen yes to opioid injection on the online screener questionnaire * Currently in probation 2. Quantitative surveys for probation and prison officers * Being 18 years or older * Being currently assigned and working as a probation or prison officer at a probation site 3. Focus Groups (People in probation) * Being 18 years or older * Screen yes to opioid injection criteria on the online screener * Currently in probation 4. Focus Groups (Probation and prison officers) * Being 18 years or older * Being currently assigned and working as a probation or prison officer at a probation * Has more than 3 months of field experience * Works at a probation site within 25 kilometers of an OAT site Exclusion Criteria: \-
Where it's running
-
Alternative Georgia
Tbilisi, Georgia Recruiting -
AIDS Foundation East-West (AFEW)
Bishkek, Kyrgyzstan Recruiting -
Ngo Afi
Chisinau, Moldova Recruiting -
Institute for International Health and Education (IIHE)
Dushanbe, Tajikistan Recruiting -
Yale University
New Haven, Connecticut, United States Not yet recruiting
Study contacts
- Principal investigator: Frederick L Altice, MD — Yale University
- Study coordinator: David Oliveros, MPH
- Email: david.oliveros@yale.edu
- Phone: 202-805-8118
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Project SHIELD 2.0: Police Education to Support Public Health in Kentucky
Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.
-
New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV
This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.
-
Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV
This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.
-
HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters
This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.
-
Stigma-reducing program to help women who use drugs stay in HIV care
This test checks whether a stigma-reduction program helps women living with HIV who use drugs stay engaged in HIV care in Ukraine.
-
Platelets and HIV Reservoirs: A look at how platelets might harbor HIV in people living with HIV
This observational study tests whether HIV can be found inside platelets in adults with suppressed HIV on therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.